RSS-Feed abonnieren
DOI: 10.1055/s-0028-1109338
© Georg Thieme Verlag KG Stuttgart · New York
Kombination von Antidepressiva – eine sinnvolle Behandlungsstrategie bei therapieresistenten Depressionen?
Combining Antidepressants: a Useful Strategy for Therapy Resistant Depression?Publikationsverlauf
Publikationsdatum:
04. Mai 2009 (online)

Zusammenfassung
Die folgende Arbeit fasst Nutzen und Risiken der bisher bekannten Kombinationsbehandlungen mit Antidepressiva bei therapieresistenten Depressionen zusammen. Die Literaturrecherche erfolgte mittels einer Medline-Datenbank-Recherche der Jahrgänge 1990 – 2006. Kombinationstherapien zweier Antidepressiva werden im klinischen Alltag sehr häufig durchgeführt. Sinnvolle Antidepressivakombinationen nutzen den Vorteil komplementärer Wirkmechanismen, um einen synergistischen Nutzen zu erzielen. Vorteile einer Kombinationstherapie bestehen in der Fortführung einer partiellen Response auf eine Monotherapie und dem gleichzeitig damit verbundenen Vermeiden der Gefahr einer Verschlechterung depressiver Symptome durch Absetzen des partiell wirksamen Antidepressivums. Nachteile dieser Strategie bestehen in dem Risiko von Arzneimittelwechselwirkungen, einer möglichen Potenzierung von unerwünschten Arzneimittelwirkungen und höheren Behandlungskosten. Obwohl Kombinationsstrategien in der klinischen Praxis oft angewandt werden, gibt es nur wenig kontrollierte Studien, um ihren Nutzen und ihre Wirksamkeit zu belegen (Evidenzlevel C, dies trifft auf alle Kombinationstherapien zu). Wichtig erscheint darauf hinzuweisen, dass die Zugabe eines SSRI zu einem Trizyklikum einen erhöhten Blutspiegel und eine verzögerte Metabolisierung des Trizyklikums herbeiführen kann, was eventuell ein erhöhtes Toxizitätsrisiko der trizyklischen Medikation nach sich führt. Die Kombination eines irreversiblen MAO-Hemmers mit Clomipramin, einem SSRI oder einem SSNRI sollte aufgrund eines möglichen Serotonin-Syndroms grundsätzlich vermieden werden.
Die detaillierte Kenntnis der dargestellten Kombinationsstrategien ermöglicht unter Umständen bessere Behandlungsergebnisse bei therapieresistenten Depressionen.
Abstract
Various pharmacological strategies have been developed to treat such refractory depression, of which combination therapies with antidepressants are one of the most important. This article reviews both benefits and risks of all known antidepressant combination strategies. The relevant literature was identified by means of a computerized MEDLINE research on the years 1990 – 2006 and scanning of review articles. The use of antidepressant combinations to overcome refractory depression is a common strategy in practice. Many antidepressants can be usefully combined especially if they engage separate mechanisms of action – like SSRIs with Reboxetine, Bupropion, Mirtazapine and Tricyclics – or on the other hand – Tricyclics with MAO-Inhibitiors. Combination strategies are effective treatment options, however they do have potential safety risks due to pharmacokinetic and pharmacodynamic interactions. Combinations including MAOIs can cause serotonin syndrome, and some SSRIs like Fluoxetine may elevate tricyclic plasma levels with the consequence of an increased risk of toxicity. The distinct knowledge of available antidepressant combination strategies may help to increase response – as well as remission rates in therapy resistant depression. However, further research is urgently needed to determine relative efficacy.
Schlüsselwörter
Antidepressiva - therapieresistente Depression - Kombinationen von Antidepressiva - Antidepressivanonresponse
Key words
antidepressants - therapy resistant depression - refractory depression - combination therapies with antidepressants
Literatur
- 1
Amsterdam J D, Hornig-Rohan M.
Treatment algorithms in treatment-resistant depression.
Psychiatr Clin North Am.
1996;
19
371-386
MissingFormLabel
- 2
Dunner D L, Rush A J, Russell J M. et al .
Prospective long-term, multicenter study of the naturalistic outcomes of patients
with treatment-resistant depression.
J Clin Psychiatry.
2006;
67
688-695
MissingFormLabel
- 3
Fawcett J.
Progress in treatment-resistant and treatment-refractory depression: we still have
a long way to go.
J Clin Psychiatry.
1994;
24
214-216
MissingFormLabel
- 4
Nelson J C.
Managing treatment-resistant major depression.
J Clin Psychiatry.
2003;
64
5-12
MissingFormLabel
- 5
Nierenberg A A, Amsterdam J D.
Treatment-resistant depression: definition and treatment approaches.
J Clin Psychiatry.
1990;
51 (Suppl 6)
39-47
MissingFormLabel
- 6
Souery D, Amsterdam J, Montigny de C. et al .
Treatment resistant depression: methodological overview and operational criteria.
Eur Neuropsychopharmacol.
1999;
9
83-91
MissingFormLabel
- 7
Thase M E, Rush A J.
When at first you don’t succeed: sequential strategies for antidepressant nonresponders.
J Clin Psychiatry.
1997;
58 (Suppl 13)
23-29
MissingFormLabel
- 8 Burrows G D, Norman T R. Treatment-resistant unipolar depression. Lader M, Naber D Difficult Clinical Problems in Psychiatry London; Martin Dunitz Ltd 1999: 57-75
MissingFormLabel
- 9
Guscott R, Grof P.
The clinical meaning of refractory depression: a review for the clinician.
Am J Psychiatry.
1991;
148
695-704
MissingFormLabel
- 10 Rush A J. Aktueller Stand und Perspektiven der Forschung. Bauer M, Berghöfer A, Adli M Akute und therapieresistente Depressionen Heidelberg; Springer 2005: 3-19
MissingFormLabel
- 11
Schmauß M, Meller I.
Die „therapieresistente” Depression – Ursachen und Behandlungsmöglichkeiten.
Psychiatr Prax.
1989;
16
101-108
MissingFormLabel
- 12 Helmchen H. Gestuftes Vorgehen bei Resistenz gegen Antidepressiva-Therapie. Möller HJ Therapieresistenz unter Antidepressiva-Behandlung Heidelberg; Springer 1990: 237-250
MissingFormLabel
- 13
Möller H J.
Therapieresistenz auf Antidepressiva: Risikofaktoren und Behandlungsmöglichkeiten.
Nervenarzt.
1991;
62
658-669
MissingFormLabel
- 14
Möller H J.
Non-response to antidepressants: risk factors and therapeutic possibilities.
In Clin Psychopharmacol.
1994;
9 (Suppl 2)
17-23
MissingFormLabel
- 15
Möller H J.
Therapieresistenz auf Antidepressiva.
Nervenarzt.
2004a;
75
499-517
MissingFormLabel
- 16
Möller H J.
Medikamentöse Therapiestrategien bei therapieresistenter unipolarer Depression.
Psychopharmakotherapie.
2004b;
11
34-41
MissingFormLabel
- 17
Sackheim H A.
The definition and meaning of treatment-resistant depression.
J Clin Psychiatry.
2001;
62 (Suppl 16)
10-17
MissingFormLabel
- 18 Möller H J. Therapieresistenz unipolarer depressiver Erkrankungen: Häufigkeit, Prädiktoren, Risikofaktoren. Berghöfer A, Adli M Akute und therapieresistente Depressionen Heidelberg; Springer 2005: 21-37
MissingFormLabel
- 19
Fava M, Davidson K G.
Definition and epidemiology of treatment-resistant depression.
Psychiatr Clin North Am.
1996;
19
179-200
MissingFormLabel
- 20
Fava M.
Augmentation and combination strategies in treatment-resistant depression.
J Clin Psychiatry.
2001;
62 (Suppl 18)
4-11
MissingFormLabel
- 21
Fredman S J, Fava M, Kienke A S. et al .
Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors
in major depression: a survey of current ”next-step” practices.
J Clin Psychiatry.
2000;
61
403-408
MissingFormLabel
- 22
McIntyre R S, Muller A, Mancini D A. et al .
What to do if an initial antidepresant fails?.
Can Fam Physician.
2003;
49
449-457
MissingFormLabel
- 23
Nelson J C.
Augmentation strategies with serotonin-noradrenergic combinations.
J Clin Psychiatry.
1998a;
59
65-68
MissingFormLabel
- 24
Nelson J C.
Treatment of antidepressant nonresponders: augmentation or switch?.
J Clin Psychiatry.
1998b;
59 (Suppl 15)
35-41
MissingFormLabel
- 25
Nelson J C.
Augmentation strategies in depression 2000.
J Clin Psychiatry.
2000;
61 (Suppl 2)
13-19
MissingFormLabel
- 26
Nemeroff C B.
Augmentation strategies in patients with refractory depression.
Depress Anxiety.
1996;
4
169-181
MissingFormLabel
- 27
Nierenberg A A, White K.
What next? A review of pharmacologic strategies for treatment resistant depression,
Psychopharmacol.
Bull.
1990;
26
429-460
MissingFormLabel
- 28
Nolen W A, Haffmans J.
Treatment of resistant depression. Review on the efficacy of various biological treatments,
specifically in major depression resistant to cyclic antidepressants.
Intern Clin Psychopharmacol.
1989;
4
217-228
MissingFormLabel
- 29
Pasternak M, Zimmerman M.
Switching versus augmentation: a prospective, naturalistic comparison in depressed
treatment resistant patients.
J Clin Psychiatry.
2001;
62
135-142
MissingFormLabel
- 30
Trivedi M H, Kleiber B A.
Algorithm for the treatment of chronic depression.
J Clin Psychiatry.
2001a;
62 (Suppl 6)
22-29
MissingFormLabel
- 31
Trivedi M H, Kleiber B A.
Using treatment algorithms for the effective management of treatment-resistant depression.
J Clin Psychiatry.
2001b;
62 (Suppl 18)
25-29
MissingFormLabel
- 32
Trivedi M H.
Treatment-resistant depression: new therapies on the horizon.
Ann Clin Psychiatry.
2003;
15
59-70
MissingFormLabel
- 33
Fava M, Rush A J.
Current status of augmentation and combination treatments for major depressive disorder:
a literature review and a proposal for a novel approach to improve practice.
Psychother Psychosom.
2006;
3
139-153
MissingFormLabel
- 34
DeBattista C.
Augmentation and combination strategies for depression.
J Psychopharmacol.
2006;
20
11-18
MissingFormLabel
- 35 Schmauß M. Kombinationstherapie nicht-selektiver Monoamin-Rückaufnahme-Inhibitoren mit MAO-Hemmern. Riederer P, Laux G, Pöldinger W Neuro-Psychopharmaka, Bd 3: Antidepressiva Phasenprophylaktika und Stimmungsstabilisierer Wien; Springer 2002: 551-557
MissingFormLabel
- 36
Dodd S, Horgan D, Malhi G S. et al .
To combine or not to combine? A literature review of antidepressant combination therapy.
J Affect Disord.
2005;
89
1-11
MissingFormLabel
- 37
Tanum L H.
Combination treatment with antidepressant in refractory depression.
Int Clin Psychopharmacoly.
1994;
9
37-40
MissingFormLabel
- 38
De la Gandara J, Aguera L, Rojo J E. et al .
Use of antidepressant combinations: which, when and why? Results of a Spanish survey.
Acta Psychiatr Scand.
2005;
112 (Suppl. 428)
32-36
MissingFormLabel
- 39
Frye M A, Ketter T A, Leverich G S. et al .
The increasing use of polypharmacotherapy for refractory mood disorders: 22 years
of study.
J Clin Psychiatry.
2000;
61
9-15
MissingFormLabel
- 40
Schmauß M, Messer T.
Augmentationsstrategien bei Therapieresistenz auf Antidepressiva.
Psychiat Prax.
2007;
34
165-174
MissingFormLabel
- 41
Murphy D L, Sunderland T, Cohen R M.
Monoamine oxidase-inhibiting antidepressants – a clinical update.
Psychiatr Clin North Am.
1984;
7
549-562
MissingFormLabel
- 42
Schuckit M, Robins E, Feighner J.
Tricyclic antidepressants and monoamine oxidase inhibitors.
Arch Gen Psychiatry.
1971;
24
509-514
MissingFormLabel
- 43 Cohen S N, Armstrong M F. Drug interactions: a handbook for clinical use. Baltimore; Williams & Wilkins 1974
MissingFormLabel
- 44
Sjöqvist F.
Psychotropic drugs II: interaction between monoamine oxidase (MAO) inhibitors and
other substances.
Proc R Soc Med.
1965;
58
967-978
MissingFormLabel
- 45
Ananth J, Luchins D A.
A review of combined tricyclic and MAOI therapy.
Compr Psychiatry.
1977;
18
121-134
MissingFormLabel
- 46
Ponto L B, Perry P J, Liskow B I. et al .
Drug therapy reviews: tricyclic antidepressant and monoamine oxidase inhibitor combination
therapy.
Am J Hosp Pharm.
1977;
34
955-961
MissingFormLabel
- 47
White K, Simpson G.
Combined MAOI-tricyclic antidepressant treatment. A reevaluation.
J Clin Psychopharmacol.
1981;
1
264-282
MissingFormLabel
- 48
White K, Simpson G.
The combined use of MAOIs and tricyclics.
J Clin Psychiatry.
1984;
45
67-69
MissingFormLabel
- 49 Marks J. Interaction involving drugs used in psychiatry. Marks J, Pare CMB The scientific basis of drug therapy in psychiatry Oxford; Pergamon 1965: 191-201
MissingFormLabel
- 50
Davidson J.
Adding a tricyclic antidepressant to a monoamine oxidase inhibitor.
J Clin Psychopharmacol.
1982;
3
216
MissingFormLabel
- 51
Lam R W, Wan D D, Cohen N L. et al .
Combining antidepressants for treatment-resistant depression. A review.
J Clin Psychiatry.
2002;
63
685-693
MissingFormLabel
- 52
Berlanga C, Ortega-Soto H A.
A 3-year follow-up of a group of treatment-resistant depressed patients with a MAOI/tricyclic
combination.
J Affect Disord.
1995;
34
187-192
MissingFormLabel
- 53
Feighner J P, Herbstein J, Damlouji N.
Combination MAOI, TCA, and direct stimulant therapy of treatment-resistant depression.
J Clin Psychiatry.
1985;
46
206-209
MissingFormLabel
- 54
Schmauß M, Kapfhammer H P, Meyr P. et al .
Combined MAO-inhibitor and tri(tetra)cyclic antidepressant treatment in therapy resistant
depression.
Prog Neuro Psychopharmacol Biol Psychiatry.
1988;
12
523-532
MissingFormLabel
- 55
Davidson J, Mc L eod MN, Law-Yone B. et al .
A comparison of electroconvulsive therapy and combined phenelzine amitriptyline in
refractory depression.
Arch Gen Psychiatry.
1978;
35
639-642
MissingFormLabel
- 56
Young J PR, Lader M H, Hughes W C.
Controlled trial of trimipramine, monoamine oxidase inhibitors, and combined treatment
in depressed outpatients.
Br Med J.
1979;
2
1315-1317
MissingFormLabel
- 57
Razzani J, White K, White J. et al .
The safety and efficacy of combined amitriptyline and tranylcypromine antidepressant
treatment.
Arch Gen Psychiatry.
1983;
40
657-661
MissingFormLabel
- 58
White K, Pistole T A, Boyd J.
Combined monoamine oxidase inhibitor tricyclic antidepressant treatment. A pilot study.
Am J Psychiatry.
1980;
137
1422-1425
MissingFormLabel
- 59
O’Brien S, McKeon P, O’Regan M.
The efficacy and tolerability of combined antidepressant treatment in different depressive
subgroups.
Br J Psychiatry.
1993;
163
363-368
MissingFormLabel
- 60 Pande A C, Calarco M M, Grunhaus L J. Combined MAOI-TCA treatment in refractory depression. Amsterdam JD Advances in neuropsychiatry and psychopharmacology, vol 2: refractory depression New York; Raven Press 1991: 115-121
MissingFormLabel
- 61
Goldberg R S, Thornton W E.
Combined tricyclic-MAOI therapy for refractory depression: a review, with guidelines
for appropriate usage.
J Clin Pharmacol.
1978;
18
143-147
MissingFormLabel
- 62
Spiker D G, Pugh D D.
Combining tricyclic and monoamine oxidase inhibitor antidepressants.
Arch Gen Psychiatry.
1976;
33
828-830
MissingFormLabel
- 63
Oefele v K, Grohmann R, Hippius H. et al .
Unerwünschte Arzneimittelwirkungen bei der Kombinationsbehandlung mit trizyklischen
Antidepressiva und Monoaminoxidase-Hemmern.
Nervenarzt.
1988;
59
118-123
MissingFormLabel
- 64
Beaumont G.
Drug interactions with clomipramine (Anafranil).
J Int Med Res.
1973;
1
480-484
MissingFormLabel
- 65
Marley E, Wozniak K M.
Clinical and experimental aspects of interactions between amine oxidase inhibitors
and amine reuptake inhibitors.
Psychol Med.
1983;
13
735-749
MissingFormLabel
- 66
Amsterdam J D, Berwish N.
Treatment of refractory depression with combination reserpine and tricyclic antidepressant
therapy.
J Clin Psychopharmacology.
1992;
7
238-242
MissingFormLabel
- 67
Hüttemann K, Nowe T, Köhrmann M. et al .
Maligne Hyperthermie und deren Differentialdiagnosen.
Fortschr Neurol Psychiat.
2009;
77
(im Druck)
MissingFormLabel
- 68
Sternbach H.
Danger of MAOI therapy after fluoxetine withdrawal.
Lancet.
1988;
II
850-851
MissingFormLabel
- 69
Feighner J P, Boyer W F, Tyler D L. et al .
Adverse consequences of fluoxetine-MAOI combination therapy, J.
Clin Psychiatry.
1990;
51
222-225
MissingFormLabel
- 70
Beasley C M, Masica D N, Heiligenstein J H. et al .
Possible monoamine oxidase inhibitor serotonin uptake inhibitor interaction: Fluoxetine
clinical data and preclinical findings.
J Clin Psychopharmacol.
1993;
13
312-320
MissingFormLabel
- 71
Hodgman M J, Martin T G, Krenzelok E P.
Serotonin syndrome due to venlafaxine and maintenance tranylcypromine therapy.
Human and Exp Toxicology.
1997;
16
14-17
MissingFormLabel
- 72
Boyer E W, Shannon Jr M.
The serotonin syndrome.
N Engl J Med.
2005;
352
1112-1120
MissingFormLabel
- 73
Steinberg R, Jost C, Weess H G. et al .
Combination of tricyclic antidepressants with moclobemide or tranylcypromine – outcome
data in therapy resistant MD.
Neuropsychopharmacology.
1994;
10 (Suppl)
62
MissingFormLabel
- 74
Koenig F, Wolfersdorf M.
Combination therapy using moclobemide with tricyclic and tetracyclic antidepressants
to treat therapy-resistant depression.
Pharmacopsychiatry.
1997;
30
93-96
MissingFormLabel
- 75
Koenig F, Wolfersdorf M, Loble M. et al .
Trimipramine and maprotiline plasma levels during combined treatment with moclobemide
in therapy-resistant depression.
Pharmacopsychiatry.
1997;
30
125-127
MissingFormLabel
- 76
Bakish D, Hooper C L, West D L. et al .
Moclobemide and specific serotonin re-uptake inhibitor combination treatment of resistant
anxiety and depressive disorders.
Hum Psychopharmacol.
1995;
10
105-109
MissingFormLabel
- 77
Joffe R T, Bakish D.
Combined SSRI-moclobemide treatment of psychiatric illness.
J Clin Psychiatry.
1994;
55
24-25
MissingFormLabel
- 78
Ebert D, Albert R, May A. et al .
Combined SSRI-RIMA treatment in refractory depression. Safety data and efficacy.
Psychopharmacology.
1995;
119
342-344
MissingFormLabel
- 79
Neuvonen P, Pohjola-Sintonen S, Tacke U. et al .
Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine
overdoses.
Lancet.
1993;
342
1419
MissingFormLabel
- 80
Hawley C J, Quick S J, Ratnam S.
Safety and tolerability of combined treatment with moclobemide and SSRI: a systematic
study of 50 patients.
Int Clin Psychopharmacol.
1996;
11
187-191
MissingFormLabel
- 81
Lejoyeux M, Adès J, Rouillon F.
Serotonin syndrome. Incidence, symptoms and treatment.
CNS Drugs.
1994;
2
132-143
MissingFormLabel
- 82
Dams R, Benijts T H, Lambert W E. et al .
A fatal case of serotonin syndrome after combined moclobemide-citalopram intoxication.
J Anal Toxicol.
2001;
25
147-151
MissingFormLabel
- 83
Volz H P, Gleiter C H, Möller H J.
Monoaminoxidasehemmer in der Psychiatrie.
Nervenarzt.
1996;
67
339-347
MissingFormLabel
- 84
Bonnet U.
Moclobemide: therapeutic use and clinical studies.
CNS Drug Rev.
2003;
9
97-140
MissingFormLabel
- 85
Weilburg J B, Rosenbaum J F, Biederman J. et al .
Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders:
a preliminary report.
J Clin Psychiatry.
1989;
50
447-449
MissingFormLabel
- 86
Vaughan D A.
Interaction of fluoxetin with tricyclic antidepressants (letter).
Am J Psychiatry.
1988;
145
1478
MissingFormLabel
- 87
Weilburg J B, Rosenbaum J F, Biedermann J. et al .
Tricyclic augmentation of fluoxetine.
Ann Clin Psychiatry.
1991;
3
209-213
MissingFormLabel
- 88 Rosenthal J S, Kaswan M J, Hemlock C. et al .Fluoxetine enhancement of heterocyclic antidepressants. Amsterdam JD Advances in neuropsychiatry and psychopharmacology, vol 2: refractory depression New York; Raven Press 1991: 105-108
MissingFormLabel
- 89
Levitt A J, Joffe R T, Kamil R. et al .
Do depressed subjects who have failed both fluoxetine and a tricyclic antidepressant
respond to the combination?.
J Clin Psychiatry.
1999;
60
613-616
MissingFormLabel
- 90
Rothschild B S.
Fluoxetine-nortriptyline therapy of treatment resistant major depression in a geriatric
patient.
J Geriatric Psych Neurol.
1994;
7
137-138
MissingFormLabel
- 91
Seth R, Jennings A L, Bindman J. et al .
Combination treatment with noradrenalin and serotonin reuptake inhibitors in resistant
depression.
Br J Psychiatry.
1992;
161
562-565
MissingFormLabel
- 92
Zajecka J M, Jeffriess H, Fawcett J.
The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant
depression: a retrospective analysis.
J Clin Psychiatry.
1995;
56
338-343
MissingFormLabel
- 93
Baron B M, Ogden A, Seigel B W. et al .
Rapid down regulation of β-adrenoreceptors by co-administration of desipramine and
fluoxetine.
Eur J Pharmacol.
1988;
154
125-134
MissingFormLabel
- 94
Nelson J C, Mazure C M, Bowers M BJ. et al .
A preliminary, open study of the combination of fluoxetine and desipramine for rapid
treatment of major depression.
Arch Gen Psychiatry.
1991;
48
303-307
MissingFormLabel
- 95
Fava M, Rosenbaum J F, Mc Grath P J. et al .
Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression:
A double blind controlled study.
Am J Psychiatry.
1994;
151
1372-1374
MissingFormLabel
- 96
Fava M, Alpert J, Nierenberg A A. et al .
Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation
of fluoxetine in partial responders and nonresponders to fluoxetine.
J Clin Psychoharmacol.
2002;
22
379-387
MissingFormLabel
- 97
Perlis R H, Iosifescu D V, Alpert J. et al .
Effect of medical comorbidity on response to fluoxetine augmentation or dose increase
in outpatients with treatment-resistant depression.
Psychosomatics.
2004;
45
224-229
MissingFormLabel
- 98
Nelson J C, Mazure C M, Jatlow P I. et al .
Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment
of depression: a double-blind, randomized study.
Biol Psychiatry.
2004;
55
296-300
MissingFormLabel
- 99 Blecourt C V de, Gudde H. Surplus value of combining antidepressants in refractory depression. Second International
Conference on Refractory Depression. Abstract Amsterdam; 24.–26. Juni 1992
MissingFormLabel
- 100
Lauritzen L, Clemmensen L, Klysner R. et al .
Combined treatment with imipramine and mianserine. A controlled pilot study.
Pharmacopsychiatry.
1992;
25
182-186
MissingFormLabel
- 101 Klysner R, Geisler A. Rapid downregulation of cerebral β-adrenoreceptors by combined treatment with imipramine
and mianserin. Amsterdam JD Advances in neuropsychiatry and psychopharmacology, vol 2: refractory depression New York; Raven Press 1991: 109-113
MissingFormLabel
- 102
Nierenberg A A, Cole J O, Glass L.
Possible trazodone potentation of fluoxetine: a case series.
J Clin Psychiatry.
1992;
53
83-85
MissingFormLabel
- 103
Maes M, Vandoolaeghe E, Desnyder R.
Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in
major depression.
J Affect Disord.
1996;
41
201-210
MissingFormLabel
- 104
Clark N A, Alexander B.
Increased rate of trazodone prescribing with bupropion and selective serotonin-reuptake
inhibitors versus tricyclic antidepressants.
Ann Pharmacother.
2000;
34
1007-1012
MissingFormLabel
- 105
Dam J, Ryde L, Svejso J. et al .
Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo
in the acute treatment of major depression.
Pharmacopsychiatry.
1998;
31
48-54
MissingFormLabel
- 106
Ferreri M, Lavergne F, Berlin I. et al .
Benefits from mianserin augmentation of fluoxetine in patients with major depression
non-responders to fluoxetine alone.
Acta Psychiatr Scand.
2001;
103
66-72
MissingFormLabel
- 107
Maes M, Libbrecht I, Hunsel van F. et al .
Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized
major depressed patients, including those with treatment resistance.
J Clin Psychopharmacol.
1999;
19
177-182
MissingFormLabel
- 108
Licht R W, Qvitzau S.
Treatment strategies in patients with major depression not responding to first-line
sertraline treatment: a randomised study of extended duration of treatment, dose increase
or mianserin augmentation.
Psychopharmacology.
2002;
161
143-151
MissingFormLabel
- 109
Harkin A, Kelly J P, McNamara M. et al .
Activity and onset of action of reboxetine and effect of combination with sertraline
in an animal model of depression.
Eur J Pharmacol.
1999;
364
123-132
MissingFormLabel
- 110 Hawley C J, Sivakumaran T, Ochocki M. et al .Coadministration therapy with reboxetine and serotonin specific reuptake inhibitors
in twenty-four patients with major depression (abstract). 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum (CINP) Brussels; 2000
MissingFormLabel
- 111
Devarajan S, Dursun S M.
Citalopram plus reboxetine in treatment-resistant depression.
Can J Psychiatry.
2000;
45
489-490
MissingFormLabel
- 112
Dursun S M, Devarajan S.
Reboxetine plus citalopram for refractory depression not responding to venlafaxine:
possible mechanisms.
Psychopharmacology.
2001;
153
497-498
MissingFormLabel
- 113
Lucca A, Serretti A, Smeraldi E.
Effect of reboxetine augmentation in SSRI resistant patients.
Hum Psychopharmacol.
2000;
15
143-145
MissingFormLabel
- 114
Rubio G, San L, Lopez-Munoz F. et al .
Reboxetine adjunct for partial or nonresponders to antidepressant treatment.
J Affect Disord.
2004;
81
67-72
MissingFormLabel
- 115
Carpenter L L, Jocic Z, Hall J M. et al .
Mirtazapine augmentation in the treatment of refractory depression.
J Clin Psychiatry.
1999;
60
45-49
MissingFormLabel
- 116
Carpenter L L, Yasmin S, Price L H.
A double-blind, placebo-controlled study of antidepresant augmentation with mirtazapine.
Biol Psychiatry.
2002;
51
183-188
MissingFormLabel
- 117 Debonnel G, Gobbi G, Turcotte J. et al .The alpha-2 antagonist mirtazapine combined with the SSRI paroxetine induces a greater
antidepressant response: a double-blind controlled study. Presented at the 39th Annual Meeting of the American College of Neuropsychopharmacology, Dec 10 – 14,. San Juan, Puerto Rico; 2000
MissingFormLabel
- 118
Farah A.
Relief of SSRI-induced sexual dysfunction with mirtazapine treatment (letter).
J Clin Psychiatry.
1999;
60
260-261
MissingFormLabel
- 119
McGrath P J, Stewart J W, Fava M. et al .
Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant
medication trials for depression: a star*D report.
Am J Psychiatry.
2006;
163
1531-1541
MissingFormLabel
- 120 Boyer W F, Feighner J P. The combined use of fluoxetine and bupropion (abstract). 146th Annual Meeting of the American Psychiatric Association. San Francisco; 1993
MissingFormLabel
- 121
Brodkin J A, Lasser R A, Wines J DJ. et al .
Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant
monotherapy.
J Clin Psychiatry.
1997;
58
137-145
MissingFormLabel
- 122
Lam R W, Hossie H, Solomons K. et al .
Citalopram and bupropion SR: combining versus switching in patients with treatment-resistant
depression.
J Clin Psychaitry.
2004;
65
337-340
MissingFormLabel
- 123
Marshall R D, Randall D, Johannet C M. et al .
Bupropion and sertraline combination treatment in refractory depression.
J Psychopharmacol.
1995;
9
284-286
MissingFormLabel
- 124
Spier S A.
Use of bupropion with SSRIs and venlafaxine.
Depress Anxiety.
1998;
7
73-75
MissingFormLabel
- 125
Papakostas G I, Worthington J J, Iosifescu D V. et al .
The combination of duloxetine and bupropion for treatment-resistant major depressive
disorder.
Depress Anxiety.
2006;
3
178-181
MissingFormLabel
- 126
Young S J.
Panic associated with combining fluoxetine and bupropion (letter).
J Clin Psychiatry.
1996;
57
177-178
MissingFormLabel
- 127
Gerner R H, Kaufman K R, Rosen R.
Seizures associated with bupropion and SSRI cotherapy (abstract).
Biol Psychiatry.
1998;
43
995
MissingFormLabel
- 128
DeBattista C, Solvason H B, Poirier J. et al .
A prospective trial of bupropion SR augmentation of partial and non-responders to
serotonergic antidepressants.
J Clin Psychopharmacol.
2003;
23
27-30
MissingFormLabel
- 129
Clayton A H, McGarvey E L, Abouesh A I. et al .
Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual
dysfunction.
J Clin Psychiatry.
2001;
62
185-190
MissingFormLabel
- 130
Kennedy S H, McCann S M, Masellis M. et al .
Combining bupropion SR with venlafaxine, paroxetine or fluoxetine: a preliminary report
on pharmacokinetic, therapeutic, and sexual dysfunction effects.
J Clin Psychiatry.
2000;
63
181-186
MissingFormLabel
- 131
Labbate L A, Grimes J B, Hines A. et al .
Bupropion treatment of serotonin reuptake antidepressant-associated sexual dysfunction.
Ann Clin Psychiatry.
1997;
9
241-245
MissingFormLabel
- 132
Papakostas G I, Petersen T J, Green C. et al .
A description of next-step switching versus augmentation practices for outpatients
with treatment-resistant major depressive disorder enrolled in an academic speciality
clinic.
Ann Clin Psychiatry.
2005;
3
161-165
MissingFormLabel
- 133
Trivedi M H, Fava M, Wisniewski S R. et al .
Medication augmentation after the failure of SSRIs for depression.
N Engl J Med.
2006;
12
1243-1252
MissingFormLabel
- 134
Zisook S A, Rush A, Haight B R.
Use of bupropion in combination with serotonin reuptake inhibitors.
Biol Psychiatry.
2006;
59
203-210
MissingFormLabel
- 135
Bondolfi G, Chautems C, Rochat B. et al .
Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences
of a fluvoxamine augmentation.
Psychopharmacology.
1996;
128
421-425
MissingFormLabel
- 136
Hunchak J.
SSRI combination: treatment for depression (letter).
Can J Psychiatry.
1994;
55
24-25
MissingFormLabel
- 137
Coryell W.
Augmentation strategies for inadequate antidepressant response: a review of placebo-controlled
studies.
Ann Clin Psychiatry.
2000;
12
141-146
MissingFormLabel
- 138
Bauer M, Linden M.
Die Kombination verschiedener Antidepressiva in der Behandlung therapieresistenter
Depressionen.
Nervenarzt.
1993;
64
343-347
MissingFormLabel
- 139
Bauer M, Whybrow P C, Angst J. et al .
WFSBP-Guidelines for biological treatment of unipolar depressive disorders, Part 1:
Acute and continuation treatment of major depressive disorder.
World J Biol Psychiatry.
2002;
3
5-43
MissingFormLabel
- 140
Härter M, Sitta P, Keller F. et al .
Stationäre psychiatrisch-psychotherapeutische Depressionsbehandlung. Prozess- und
Ergebnisqualität anhand eines Modellprojekts in Baden-Württemberg.
Nervenarzt.
2004;
75
1083-1091
MissingFormLabel
Prof. Dr. Max Schmauß
Bezirkskrankenhaus Augsburg
Dr.-Mack-Str. 1
86156 Augsburg
eMail: m.schmauss@bkh-augsburg.de